SESSION TITLE: Late-Breaking Abstracts
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Tuesday, October 28, 2014 at 08:45 AM - 10:00 AM
PURPOSE: A treatment goal of the Global Initiative for Chronic Obstructive Lung Disease for patients with chronic obstructive pulmonary disease (COPD) is improvement of respiratory symptoms. The modified British Medical Research Council (mMRC) dyspnea scale and the COPD Assessment Test (CAT) are validated measures of respiratory health status. A score of ≥2 on the mMRC is indicative of greater dyspnea and a score of ≥10 on the CAT is indicative of medium to very high impact of respiratory symptoms on health status. The NIOV System has been previously shown to significantly improve respiratory muscle unloading, dyspnea, and exercise tolerance. This retrospective cohort study evaluated the impact of the NIOV System on patient mMRC and CAT scores.
METHODS: A NIOV system was administered to patients with chronic lung disease who were otherwise optimized on medical therapy. Twelve patients completed both the mMRC and CAT questionnaires approximately 1 year before treatment and 1 year after the addition of the NIOV System. A comparison of these values was performed.
RESULTS: A total of 20 patients are currently enrolled in this study, with interim results available from 12 patients. Data collection for the entire sample of 20 patients will be completed by September 2014. Of these twelve, 10 had COPD, one had pulmonary hypertension, one had bronchiolitis obliterans (n=1). The mean patient age was 72.3 years, with a mean elapsed time of 16.8 months from diagnosis to initiation of the NIOV System. Prior to initiation of the NIOV System, the mean mMRC score was 3.3 (range, 2-4) and the mean CAT score was 27.2 (range, 10-37). Average time using the NIOV System was 11 months. One year following addition of the NIOV System to usual care, the mean mMRC score declined to 1.7 (range, 0-4) and the mean CAT score decreased to 14.5 (range, 4-27).
CONCLUSIONS: Patients with severe symptoms of respiratory insufficiency report significant improvements in their respiratory symptoms and health status after the addition of the NIOV System to their standard medical therapy.
CLINICAL IMPLICATIONS: The use of a NIOV System significantly improved dyspnea and the impact of respiratory insufficiency. By reducing symptoms with the use of this system a patient may ultimately be able to enhance general exercise tolerance, increase the ability to participate in pulmonary rehabilitation, increase the ability to engage in activities of daily living, and improve overall health related quality of life.
DISCLOSURE: Brian Carlin: Consultant fee, speaker bureau, advisory committee, etc.: Breathe Technologies - speaker's bureau (sponsorhip of a talk that I gave at a respiratory care meeting in San Antonio 2013) Kevin Farberow: Consultant fee, speaker bureau, advisory committee, etc.: Breathe Technologies, Organization compensated for project related services. The following authors have nothing to disclose: Larry Casey
No Product/Research Disclosure Information